accelerated hair loss; this case was received via a regulatory authority (reference number: gb-mhra-adr 26613987) on 27-feb-2022 and was forwarded to moderna on 27-feb-2022. this regulatory authority case was reported by a consumer and describes the occurrence of alopecia (accelerated hair loss) in a 45-year-old female patient who received mrna-1273 (moderna covid-19 vaccine) for covid-19 immunisation. no medical history information was reported. on an unknown date, the patient received dose of mrna-1273 (moderna covid-19 vaccine) (unknown route) 1 dosage form. on 30-apr-2021, the patient experienced alopecia (accelerated hair loss) (seriousness criterion medically significant). at the time of the report, alopecia (accelerated hair loss) had not resolved. patient's lmp was 16-feb-2022. no concomitant medications was reported. no treatment medication was provided. patient noticed her hair became thinner and thinner. she lost approx 1/3 of her previously thick hair. medicine was obtained in a medical facility. this reaction was occurred as a result of a mistake made in the administration of the vaccine. company comment: this is a regulatory authority case concerning a 45-year-old female patient, with no medical history reported, who experienced the unexpected and serious (medically significant) event of alopecia. the event occurred on a date after a dose of mrna-1273 vaccine. patient reports that she noticed her hair became thinner and thinner, and that she lost approximately 1/3 of her previously thick hair. at the time of the report, the event had not resolved. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report.; sender's comments: this is a regulatory authority case concerning a 45-year-old female patient, with no medical history reported, who experienced the unexpected and serious (medically significant) event of alopecia. the event occurred on a date after a dose of mrna-1273 vaccine. patient reports that she noticed her hair became thinner and thinner, and that she lost approximately 1/3 of her previously thick hair. at the time of the report, the event had not resolved. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report